News

The phase 3 randomised, double-blind and placebo-controlled study will assess the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licenced from Incyte, in hospitalised adults with Covid-19.

With today’s agreement, the IVA aims to accelerate the supply of the vaccine and to make it available to other European countries that wish to participate in the

The approval allows the dispersible tablet formulation of dolutegravir, in combination with other antiretroviral treatments, to be used in treatment-naïve paediatric patients aged more than four weeks and

DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, a modulator of Wnt/Beta-catenin signaling. “Orphan Drug Designation for DKN-01

Under the terms of the agreement, the Danish pharmaceutical firm will acquire all outstanding shares of Corvidia Therapeutics for an upfront payment of $725m in cash. The company

Takeda will receive $266m upfront in cash and up to an additional $12 million USD in potential milestone payments, subject to customary legal and regulatory closing conditions. The

ATHENA is the first front-line switch maintenance study designed to show PARP monotherapy and PARP/PD-1 combination therapy in one study design. “The completion of target patient enrollment in

“Up to twenty percent of children are affected by atopic dermatitis and there remains a significant unmet need for new treatment options that may improve their care,” said

The approval allows Kalydeco to be used for the treatment of children and adolescents with CF aged between six months and older with a weight of at least